Status:
COMPLETED
LEO 29102 Single and Multiple Dose Study by Dermal Application
Lead Sponsor:
LEO Pharma
Conditions:
Atopic Dermatitis
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects. The study ...
Eligibility Criteria
Inclusion
- Male adults between the age of 18 and 55 years (both inclusive) and with a BMI between 19 and 30 kg/m2 (both inclusive).
- Subjects must be healthy as determined by medical history, physical examination, electrocardiogram (ECG), blood pressuer and heart rate, and clinical laboratory evaluation.
Exclusion
- Subjects who show signs of eczema or other skin lesions.
- Subjects who have any clinical signs of allergic diseases (excluding non active hay fever).
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00891709
Start Date
March 1 2009
End Date
June 1 2009
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LCG Bioscience
Bourn, Cambridgeshire, United Kingdom, CB23 2TN